• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ATS Roundup: Emulate models viral infection in “asthma-on-a-chip”

May 24, 2017 By Sarah Faulkner

Pulmonx touts data for Zephyr endobronchial valves in emphysema patients

Pulmonx Zephyr endobronchial valve

Pulmonx highlighted data from 2 clinical trials of its Zephyr endobronchial valve in emphysema patients without collateral ventilation. Data from the Transform and Impact trials showed clinically meaningful improvements in lung function in patients with either homogeneous or heterogeneous distribution of emphysema.

Zephyr endobronchial valves are minimally-invasive, 1-way valves that are placed in the airways of lungs to occlude diseased regions and reduce lung hyperinflation. The tiny devices help healthier regions function more efficiently, according to Pulmonx.

In both trials, patients were chosen based on the absence of collateral ventilation – airflow between regions of the lung that bypasses normal airways.

The Transform trial enrolled 97 patients with heterogeneous emphysema and randomized them to receive Zephyr valve treatment or standard of care. After 6 months, 56.3% of patients treated with Zephyr valves experienced 12% or greater improvement in lung function from baseline, compared to 3.2% of patients in the control group. Researchers also observed significant improvements in exercise capacity and quality of life in patients treated with Pulmonx’s valves.

“The magnitude of benefits to patients in this pan-European trial are dramatic and reinforce results published from prior single center studies,” principal investigator Dr. Samuel Kemp said in prepared remarks. “Using Chartis for patient selection enabled us to accurately identify patients without collateral ventilation, which is a key predictor for good outcomes with this device.”

The Impact study enrolled 93 patients with severe homogeneous emphysema and randomized them to receive Zephyr valve treatment or medical management. Consistent with previous data, patients experienced improvements in lung function, exercise capacity and quality of life when treated with the company’s devices.

In both studies, the most common side effect of the valves was pneumothorax and COPD exacerbations in the immediate time following the procedure.

“For patients with severe emphysema, there were previously few therapeutic options,” Pulmonx CEO Glen French said. “Now, we have consistent data from 4 randomized studies showing that, regardless of disease heterogeneity, when patients are selected for the absence of collateral ventilation, they can gain substantial benefits in quality of life, exercise capacity and lung function with Zephyr valves.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Emulate Inc, Merck, Mylan, pulmonx, Sunovion Pharmaceuticals, Theravance Biopharma

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS